Becton Dickinson's EnCor EnCompass system won FDA 510(k) clearance with high/low vacuum and 360-degree sampling, launching early 2026. BDX's 4.44% weight in iShares US Medical Devices ETF means these FDA-clearance developments and a projected Q4 EPS of $2.82 (down from $3.43) could sway the fund's performance.